Cognitive Disorders:  Lexicon’s LX6171 drug candidate is under evaluation as a potential treatment for cognitive disorders.  LX6171 acts by targeting a membrane protein expressed exclusively in the central nervous system. 

Highlighted areas of the brain are important in learning and memory. 
















About the Disease
Cognitive disorders significantly impair memory and other mental functions, and are often progressively debilitating.  A variety of disorders are characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia and vascular dementia. 

About the Market
According to the National Institutes of Health (NIH), Alzheimer's disease is one form of cognitive impairment that affects 4.5 million Americans, and the number of cases continues to rise as the population ages.  Vascular dementia is the second most common cause of dementia in the elderly, accounting for 20% of all dementia cases.  Cognitive impairment is also a critical issue for the millions of Americans suffering from schizophrenia.